Andrew Hall

Andrew Hall is an Oncology Discovery Safety Specialist at AstraZeneca, where they investigate mitochondrial function and reactive oxygen species generation using novel probes and mitochondrial-targeted compounds. Previously, they served as an Associate Director, focusing on in vitro cardiac safety and the discovery phase of small molecule oncology projects. They completed a PhD in Cardiovascular Science at King's College London and worked as a Postdoctoral Researcher at UCL, where they investigated mitochondrial dynamics in cardiac ischemia reperfusion injury. Additionally, their experience includes roles as an Investigator Scientist at the MRC Mitochondrial Biology Unit and a Senior Research Scientist in cardiac safety.